Apolipoprotein A-I as a candidate serum marker for the response to lithium treatment in bipolar disorder

Proteomics

Volumn 11, Issue 2, 2011, Pages 261-269

  Sussulini, Alessandra ^a,b   Dihazi, Hassan ^c   Banzato, Claudio Eduardo Muller ^a   Arruda, Marco Aurelio Zezzi ^a   Stühmer, Walter ^b,d   Ehrenreich, Hannelore ^b,d   Jahn, Olaf ^b,d   Kratzin, Hartmut D ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d Deutsche Forschungsgemeinschaft   (Germany)

Author keywords

Apolipoprotein A I; Biomarker; Biomedicine; Bipolar disorder; Lithium; Serum

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; LITHIUM;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; UPREGULATION;

ADULT; AMINO ACID SEQUENCE; ANTIPSYCHOTIC AGENTS; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; BIPOLAR DISORDER; FEMALE; HUMANS; LITHIUM; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROTEOME; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78650778931     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000371     Document Type: Article

References (27)

1. Belmaker, R. H., Medical progress: bipolar disorder. N. Engl. J. Med. 2004, 351, 476-486.
2. Marmol, F., Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular mechanisms of the therapeutic effects of lithium. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 1761-1771.
3. Oswald, P., Souery, D., Kasper, S., Lecrubier, Y. et al., Current issues in bipolar disorder: a critical review. Eur. Neuropsychopharmacol. 2007, 17, 687-695.
4. Phillips, M. L., Vieta, E., Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr. Bull. 2007, 33, 893-904.
5. Leahy, R. L., Bipolar disorder: causes, contexts, and treatments. J. Clin. Psychol. 2007, 63, 417-424.
6. Detera-Wadleigh, S. D., MacMahon, F. J., G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis. Biol. Psychiatry 2006, 60, 106-114.
7. Maj, M., The effect of lithium in bipolar disorder: a review of recent research evidence. Bipolar Disord. 2003, 5, 180-188.
8. Novikova, S. I., He, F., Cutrufello, N. J., Lidow, M. S., Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiol. Dis. 2006, 23, 61-76.
9. 1H NMR spectroscopy and chemometrics. Anal. Chem. 2009, 81, 9755-9763.
10. Huang, J. T. J., Wang, L., Prabakaran, S., Wengenroth, M. et al., Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol. Psychiatry 2008, 13, 1118-1128.
11. Levin, Y., Wang, L., Schwarz, E., Koethe, D. et al., Global proteomic profiling reveals altered proteomic signature in schizophrenia serum. Mol. Psychiatry 2010, 15, 1088-1100.
12. Miller, J. C., Miller, J. N., Statistics and Chemometrics for Analytical Chemistry, Pearson Prentice Hall, New Jersey 2005.
13. Dihazi, H., Muller, C. A., Mattes, H., Muller, G. A., Proteomic analysis to improve adequacy of hemo- and peritoneal dialysis: removal of small and high molecular weight proteins with high- and low-flux filters or a peritoneal membrane. Proteomics Clin. Appl. 2008, 2, 1167-1182.
14. Boschetti, E., Righetti, P. G., The ProteoMiner in the proteomic arena: a non-depleting tool for discovering low-abundance species. J. Proteomics 2008, 71, 255-264.
15. Wessel, D., Flügge, U. I., A method for the quantitative recovery of protein in dilute-solution in the presence of detergents and lipids. Anal. Biochem. 1984, 138, 141-143.
16. Werner, H. B., Kuhlmann, K., Shen, S., Uecker, M. et al., Proteolipid protein is required for transport of Sirtuin 2 into CNS myelin. J. Neurosci. 2007, 27, 7717-7730.
17. Jahn, O., Hesse, D., Reinelt, M., Kratzin, H. D., Technical innovations for the automated identification of gel-separated proteins by MALDI-TOF mass spectrometry. Anal. Bioanal. Chem. 2006, 386, 92-103.
18. Brechlin, P., Jahn, O., Steinacker, P., Cepek, L. et al., Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 2008, 8, 4357-4366.
19. Siedel, J., Schlefer, S., Rosseneu, M., Bergeaud, R. et al., Immunoturbidimetric method for routine determinations of apolipoproteins A-I, AII, and B in normo- and hyperlipemic sera compared with immunonephelometry. Clin. Chem. 1988, 34, 1821-1825.
20. Diz, A. P., Truebano, M., Skibinski, D. O., The consequences of sample pooling in proteomics: an empirical study. Electrophoresis 2009, 30, 2967-2975.
21. Kunitake, S. T., Chen, G. C., Kung, S. F., Schilling, J. W. et al., Pre-beta high density lipoprotein - unique disposition of apolipoprotein A-I increases susceptibility to proteolysis. Arteriosclerosis 1990, 10, 25-30.
22. Berrettini, W. H., Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol. Psychiatry 2000, 48, 531-538.
23. Dean, B., Digney, A., Sundram, S., Thomas, E. et al., Plasma apolipoprotein E is decreased in schizophrenia spectrum and bipolar disorder. Psychiatry Res. 2008, 158, 75-78.
24. Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S. et al., Omega-3 fatty acids in bipolar disorder. Arch. Gen. Psychiatry 1999, 56, 407-412.
25. Turnbull, T., Cullen-Drill, M., Smaldone, A., Efficacy of omega-3 fatty acid supplementation on improvement of bipolar symptoms: a systematic review. Arch. Psychiatry Nursing 2008, 22, 305-311.
26. Pecks, U., Seidenspinner, F., Röwer, C., Reimer, T. et al., Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals. J. Am. Soc. Mass Spectrom. 2010, 21, 1699-1711.
27. Grandjean, E. M., Aubry, J. M., Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2000, 23, 397-418.